Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTH Effect on VEGF in Healthy Children
NCT03709381Phase 1Completed
- Sponsor
- Nationwide Children's Hospital
- Start
- Oct 2017
- Primary completion
- Oct 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tetracosactide hexaacetate in adrenal insufficiency (AI), osteopenia, osteoporosis and 2 more, sponsored by Nationwide Children's Hospital. Primary endpoint: Difference between VEGF levels at baseline and the peak VEGF level after low dose cosyntropin administration at 60 minutes. Started Oct 2017; status: completed.
02
Drugs
tetracosactide hexaacetate
03
Conditions
adrenal insufficiency (AI)osteopeniaosteoporosisosteonecrosisSecondary adrenal insufficiency (SAI)
Beyond the preview
Go deeper on NCT03709381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03709381.